申请人:Celgene International II SÀRL
公开号:US10034886B2
公开(公告)日:2018-07-31
Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound):
where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.
本研究提供了调节胰高血糖素样肽 1(GLP-1)受体的化合物及其合成方法,以及治疗和/或预防使用方法。此类化合物可单独作为 GLP-1 受体的调节剂或增效剂,或与 GLP-1(7-36) 和 GLP-1(9-36)等增量肽一起使用,或与艾塞那肽和利拉鲁肽等肽类疗法一起使用,并具有以下一般结构(其中""代表化合物的 R 和 S 形式中的一种或两种):
其中 A、B、C、Y1、Y2、Z、R1、R2、R3、R4、R5、W1、n、p 和 q 如本文所定义。